间充质干细胞联合他汀类药物在糖尿病视网膜病变中的应用研究进展  

Application researches of mesenchymal stem cells combined with statins in diabetic retinopathy

作　　者：武斌[1] 陈松[1] 

机构地区：[1]天津市眼科医院天津市眼科学与视觉科学重点实验室天津市眼科研究所天津医科大学眼科临床学院,300020

出　　处：《中华实验眼科杂志》2017年第7期660-663,共4页Chinese Journal Of Experimental Ophthalmology

基　　金：天津市科技计划项目（13ZCZDSY01500）

摘　　要：糖尿病视网膜病变（DR）是糖尿病患者常见的眼部并发症，也是成人盲的主要原因之一。DR现有的治疗方法包括手术和激光治疗等不能从根本上治疗DR。近年研究发现应用间充质干细胞（MSCs）对DR进行细胞治疗具有广泛的应用前景。MSCs具有再生潜能并在视网膜的修复中起作用，但移植后MSCs的生存能力及归巢能力差，降低了其治疗效率。他汀类药物除具有调脂作用外，还能促进MSCs的增生并抑制MSCs凋亡。本文就MSCs联合他汀类药物在DR治疗中的应用及机制进行综述。Diabetic retinopathy （DR） is a common complication of eye in diabetics and is one of the major causes of blindness in adults. The current treatments of DR include surgery and laser therapy, but this does not fundamentally cure DR. Recent studies have found that mesenchymal stem ceils （MSCs） for cell therapy to DR have a wide range of applications. MSCs have regenerative potential and play a role in the repairment of the retina,but the survival and homing ability of MSCs are poor after transplantation,which reduces the therapeutic efficiency of MSCs. Statins have a variety of beneficial effects independent of lipid regulation,which can promote the proliferation of MSCs and inhibit the apoptosis of MSCs. This paper reviewed the application and mechanism of MSCs combined with statins in the treatment of DR.

关 键 词：糖尿病视网膜病变/治疗 间充质干细胞 他汀类药物 细胞治疗 移植 

分 类 号：R587.2[医药卫生—内分泌]